JP2007500757A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500757A5
JP2007500757A5 JP2006533806A JP2006533806A JP2007500757A5 JP 2007500757 A5 JP2007500757 A5 JP 2007500757A5 JP 2006533806 A JP2006533806 A JP 2006533806A JP 2006533806 A JP2006533806 A JP 2006533806A JP 2007500757 A5 JP2007500757 A5 JP 2007500757A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
spinal cord
recovery
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006533806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500757A (ja
JP4963607B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/019139 external-priority patent/WO2004110387A2/en
Publication of JP2007500757A publication Critical patent/JP2007500757A/ja
Publication of JP2007500757A5 publication Critical patent/JP2007500757A5/ja
Application granted granted Critical
Publication of JP4963607B2 publication Critical patent/JP4963607B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006533806A 2003-06-12 2004-06-14 神経再生及び機能回復のためのシグマリガンド Expired - Fee Related JP4963607B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47832903P 2003-06-12 2003-06-12
US47873503P 2003-06-12 2003-06-12
US60/478,735 2003-06-12
US60/478,329 2003-06-12
US49813203P 2003-08-26 2003-08-26
US60/498,132 2003-08-26
US55261304P 2004-03-12 2004-03-12
US60/552,613 2004-03-12
PCT/US2004/019139 WO2004110387A2 (en) 2003-06-12 2004-06-14 Sigma ligands for neuronal regeneration and functional recovery

Publications (3)

Publication Number Publication Date
JP2007500757A JP2007500757A (ja) 2007-01-18
JP2007500757A5 true JP2007500757A5 (enExample) 2007-07-26
JP4963607B2 JP4963607B2 (ja) 2012-06-27

Family

ID=33556648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533806A Expired - Fee Related JP4963607B2 (ja) 2003-06-12 2004-06-14 神経再生及び機能回復のためのシグマリガンド

Country Status (5)

Country Link
US (4) US20050020483A1 (enExample)
EP (2) EP1644026A4 (enExample)
JP (1) JP4963607B2 (enExample)
CA (1) CA2528160C (enExample)
WO (3) WO2004110389A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107432A1 (en) * 2002-01-22 2005-05-19 Yoichi Iimura Sigma receptor binder containing indanone derivative
US20060052386A1 (en) * 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery
WO2004110389A2 (en) 2003-06-12 2004-12-23 Agy Therapeutics, Inc. Sigma ligands for neuronal regeneration and functional recovery
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
WO2006050511A2 (en) * 2004-11-03 2006-05-11 University Of North Texas Health Science Center At Fort Worth Butyrophenomenes and sigma-1 receptor antagonists protect against oxidatives-stress
CA2607598A1 (en) * 2005-06-06 2006-12-14 University Of South Florida Treatment with sigma receptor agonists post-stroke
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
JP2009504648A (ja) * 2005-08-09 2009-02-05 株式会社エムズサイエンス ピペラジン誘導体
US7758954B2 (en) * 2005-08-18 2010-07-20 James Hardie Technology Limited Coated substrate having one or more cross-linked interfacial zones
US20070142396A1 (en) * 2005-12-16 2007-06-21 Vela Pharmaceuticals, Inc. Treatment of pain with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof
US20070160975A1 (en) * 2006-01-09 2007-07-12 University Of South Florida Method for the Identification of Drugs to Treat Stroke at Delayed Timepoints
NZ570078A (en) 2006-01-27 2011-10-28 Ms Science Corp Piperidine and piperazine derivatives
KR20110008166A (ko) * 2008-02-18 2011-01-26 라보라토리오스 델 드라. 에스테브.에스.에이. 화학요법의 결과로 발생하는 신경병적 통증의 치료를 위한 시그마 수용체 리간드에 결합하는 화합물들의 용도
EP2252608A4 (en) 2008-02-29 2012-10-03 Vm Discovery Inc METHOD FOR TREATING PAIN SYNDROME AND OTHER SUFFERING
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
WO2010048164A2 (en) * 2008-10-20 2010-04-29 University Of South Florida N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints
AU2009310926A1 (en) * 2008-10-27 2010-05-06 M's Science Corporation Cyclohexylamine derivative containing phenyl group, and therapeutic agent for diseases accompanied by central nervous system disorders
BRPI1007624A2 (pt) 2009-04-09 2016-07-26 Cognition Therapeutics Inc composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste
CN102595884B (zh) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 认知衰退的抑制剂
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US20130108645A1 (en) * 2010-04-13 2013-05-02 The Johns Hopkins University Methods for enhancing axonal regeneration
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
JP2014529613A (ja) * 2011-08-25 2014-11-13 コグニションセラピューティクス，インコーポレイテッド 神経変性疾患を治療する組成物及び方法
KR101129303B1 (ko) * 2011-10-19 2012-03-26 경희대학교 산학협력단 플루옥세틴을 유효성분으로 함유하는 중추신경계 질환의 예방 및 치료용 약학적 조성물
WO2013166307A2 (en) * 2012-05-02 2013-11-07 University Of South Florida N,n'-di-1 naphthylguanidine hcl (nagh) and n,n'-di-p-nitrophenylguanidine hcl (nad) treatment for stroke at delayed timepoints
US9828593B2 (en) 2012-05-16 2017-11-28 Sanbio, Inc. Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
CA2933511A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations
DK3498692T3 (da) 2014-01-31 2022-05-16 Cognition Therapeutics Inc Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
SI3413870T1 (sl) * 2016-02-11 2021-12-31 Sigmathera Sas Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni
US10954217B2 (en) 2016-04-29 2021-03-23 Board Of Regents, The University Of Texas System Sigma receptor binders
BR112019023851A2 (pt) 2017-05-15 2020-08-18 Cognition Therapeutics, Inc. compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020047185A1 (en) * 2018-08-31 2020-03-05 Texas Tech University System Enhancers of neurolysin activity
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
CN111848549B (zh) * 2019-04-29 2022-04-22 苏州大学 芳基肟类化合物及其制备和应用
IL303592A (en) * 2020-12-11 2023-08-01 Cognition Therapeutics Inc Compositions for treating dry age-related macular degeneration (amd)
US20250002503A1 (en) * 2021-09-20 2025-01-02 Esteve Pharmaceuticals, S.A. Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection
US20250134902A1 (en) * 2022-02-09 2025-05-01 Univesrity Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055470A (en) * 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
US5005470A (en) * 1989-11-09 1991-04-09 Denker James G Portable work station
US5229394A (en) * 1990-07-30 1993-07-20 Arch Development Corporation Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
WO1993009094A1 (en) 1991-10-30 1993-05-13 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
US5428037A (en) 1993-04-09 1995-06-27 Syntex Pharmaceuticals, Ltd. Heterocyclic derivatives in the treatment of Ischaemia and related diseases
CA2166100A1 (en) * 1993-06-23 1995-01-05 Richard A. Glennon Sigma receptor ligands and the use thereof
ES2151930T3 (es) * 1993-07-28 2001-01-16 Santen Pharmaceutical Co Ltd Nuevos derivados de 1,4-(difenilalquil)piperazina.
GB9416571D0 (en) * 1994-08-16 1994-10-12 Battelle Memorial Institute Novel alkylamino derivatives as sigma 2 selective ligands
UA64769C2 (uk) * 1997-11-07 2004-03-15 Х. Луннбек А/С Гідрогалогеніди 1'-[4-[1-(4-фторофеніл)-1н-індол-3-іл]-1-бутил]-спіро[ізобензофуран-1(3н),4'-піперидину], фармацевтична композиція та спосіб лікування
HUP0101706A3 (en) * 1998-04-07 2003-03-28 Lundbeck & Co As H Use of 1'-[4-[1-(4-fluorphenyl)-1h-indole-3-yl]-1-butyl]-spiro[isobenzo-furan-1(3h),4'-piperidine] for the preparation of pharmaceutical composition treating panic attacks
US20030087840A1 (en) * 1998-05-19 2003-05-08 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
WO2004110389A2 (en) * 2003-06-12 2004-12-23 Agy Therapeutics, Inc. Sigma ligands for neuronal regeneration and functional recovery
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
US20060052386A1 (en) * 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery

Similar Documents

Publication Publication Date Title
JP2007500757A5 (enExample)
CA2528160A1 (en) Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
AU2019213454B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
WO2003103583A8 (en) METHOD OF USING BIS (POLYHYDROXYPHENYLES) AND CORRESPONDING, FIXED O-ALKYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM
JP2009506069A5 (enExample)
JP5837726B1 (ja) アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤
WO2007061750A3 (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
RU2007119585A (ru) Производные рапамицина и их применение при лечении неврологических заболеваний
WO2008151841A3 (en) Treatment for alzheimer' s disease
WO2004087116A3 (es) Combinación de drogas para la disfunción motora en la enfermedad de parkinson
WO2003077869A3 (en) Neuroprotective spirostenol pharmaceutical compositions
JP2020526591A5 (enExample)
JP2011516588A5 (enExample)
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
JP2005524696A5 (enExample)
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
JP2009500397A5 (enExample)
WO2003030836A3 (en) Neuronal regeneration
JP2009532369A5 (enExample)
WO2008070284A3 (en) Amyloid beta peptides and methods of uses thereof
RU2007112950A (ru) Новые производные 3,5-секо-4-норхолестана и их применение
JPWO2006006617A1 (ja) 中枢神経疾患発症後の機能障害の回復促進剤
Bruetsch et al. THE PARKINSONIAN SYNDROME DUE TO TRAUMA*: A Clinico-Anatomical Study of A Case
SE0004455D0 (sv) Method for neuron regeneration in the central nervous system
WO2008131411A3 (en) Stimulating neuronal growth using brevetoxins